News
Important Only
Zymeworks Outlines Strategic Priorities And Outlook For 2026
Jan 11 (Reuters) - Zymeworks Inc ZYME.O:ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026ZYMEWORKS: UP TO $440 MILLION IN MILESTONE PAYMENTS ELIGIBLE TO BE EARNED RELATED TO REGULATORY APPROVALS OF ZIIHERA IN GEA IN UNITED STATES, EUROPE, JAPAN, & CHINAZYMEWORKS INC: GLOBAL PHASE 1 CL...Reuters
Sun, Jan 11
Microsoft Says Claude In Microsoft Foundry Advances Capabilities For Healthcare And Life Sciences Customers
Jan 11 (Reuters) - Microsoft Corp MSFT.O:MICROSOFT: CLAUDE IN MICROSOFT FOUNDRY ADVANCES CAPABILITIES FOR HEALTHCARE AND LIFE SCIENCES CUSTOMERSSource text: https://tinyurl.com/4z76khaaReuters
Sun, Jan 11
Teva And Royalty Pharma Enter Agreement To Accelerate Development Of Potential Treatment For Vitiligo
Jan 11 (Reuters) - Royalty Pharma PLC RPRX.O:TEVA AND ROYALTY PHARMA ENTER AGREEMENT TO ACCELERATE DEVELOPMENT OF POTENTIAL TREATMENT FOR VITILIGOTEVA - TEVA TO SHARE TEV-'408 TRIAL RESULTS IN 2026ROYALTY PHARMA - TO PROVIDE UP TO $500 MILLION FOR TEVA'S TEV-'408ROYALTY PHARMA : TEV-...Reuters
Sun, Jan 11
Allegiant to acquire Sun Country Airlines for $1.5 billion
Jan 11 (Reuters) - Low-cost airline Allegiant ALGT.O will acquire Sun Country Airlines SNCY.O in a deal valued at about $1.5 billion, including debt, the companies said on Sunday.As part of the agreement, Sun Country shareholders will receive 0.1557 Allegiant shares and $4.10 in cash for each share,...Reuters
Sun, Jan 11
Guardant Health Q4 Total Revenue Of Approx $280 Million
Jan 11 (Reuters) - Guardant Health Inc GH.O:GUARDANT HEALTH ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 RESULTSGUARDANT HEALTH Q4 REVENUE USD 280 MILLION VS. IBES ESTIMATE USD 250.4 MILLIONGUARDANT HEALTH INC: QTRLY TOTAL REVENUE OF APPROXIMATELY $280 MLN, AN INCREASE OF 39%Reuters
Sun, Jan 11
Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises
Jan 11 (Reuters) - Beam Therapeutics Inc BEAM.O:BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITIONBEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCE...Reuters
Sun, Jan 11
Day One Says OJEMDA 2026 U.S. Net Product Revenue Projected To Be $225 - $250 Million
Jan 11 (Reuters) - Day One Biopharmaceuticals Inc DAWN.O:DAY ONE ANNOUNCES PRELIMINARY 2025 OJEMDA™ NET PRODUCT REVENUE AND PROVIDES 2026 NET PRODUCT REVENUE GUIDANCEDAY ONE BIOPHARMACEUTICALS INC - OJEMDA 2026 U.S. NET PRODUCT REVENUE PROJECTED TO BE $225 - $250 MILLIONReuters
Sun, Jan 11
REUTERS NEWS SCHEDULE AT 10 p.m GMT/5 p.m ET
Here are the top stories and upcoming coverage plans for Reuters text service as of 10 p.m GMT/5 p.m ET. For a full schedule of news and events, go to our editorial calendar on Reuters Connect.TOP STORIESGLOBALIRAN-ECONOMY-PROTESTS/ Deaths from Iran protests reach more than 500, rights groupsaysDUBA...Reuters
Sun, Jan 11
Hong Kong media tycoon Jimmy Lai's mitigation hearing set to begin ahead of sentencing
Lai was found guilty under national security law in DecemberTycoon, now 78, faces potential life sentenceFamily says his health has deteriorated after more than 1,800 days in prisonCourt will also hear mitigation for eight other defendants who pleaded guiltyBy Jessie Pang and James Pomfret HONG K...Reuters
Sun, Jan 11
Allegiant to acquire Sun Country Airlines for $1.5 billion
Jan 11 (Reuters) - Low-cost airline Allegiant ALGT.O will acquire Sun Country Airlines SNCY.O in a deal valued at about $1.5 billion, including debt, the companies said on Sunday.As part of the agreement, Sun Country shareholders will receive 0.1557 Allegiant shares and $4.10 in cash for each share,...Reuters
Sun, Jan 11
Sun Country Airlines Says Allegiant And Sun Country Airlines To Merge
Jan 11 (Reuters) - Allegiant Travel Co ALGT.O:SUN COUNTRY AIRLINES - ALLEGIANT AND SUN COUNTRY AIRLINES TO MERGESUN COUNTRY AIRLINES - ALLEGIANT TO BUY SUN COUNTRY AT $18.89 PER SHARESUN COUNTRY AIRLINES - DEAL VALUES SUN COUNTRY AT $1.5 BILLIONSUN COUNTRY AIRLINES - ALLEGIANT SHAREHOLDERS TO OWN 67...Reuters
Sun, Jan 11
Olympics-Malinin headlines US figure skating team for Milano Cortina, Naumov gets nod
Jan 11 (Reuters) - Ilia Malinin unsurprisingly headlined the U.S. Olympic figure skating team that was announced on Sunday and included Maxim Naumov, whose parents died last January in a midair plane crash that devastated the figure skating community.Malinin, who was left off the Olympic team four y...Reuters
Sun, Jan 11
Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026
Jan 11 (Reuters) - MBX Biosciences Inc MBX.O:MBX BIOSCIENCES TO PROVIDE 2026 OUTLOOK AND BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEMBX BIOSCIENCES INC - PHASE 3 TRIAL OF CANVUPARATIDE TO START IN Q3 2026MBX BIOSCIENCES INC - PHASE 1 DATA FOR MBX 4291 EXPECTED IN Q4 2026MBX BIOS...Reuters
Sun, Jan 11
Exelixis Says Fiscal Year 2026 Net Product Revenues Guidance Of $2.325 Billion - $2.425 Billion
Jan 11 (Reuters) - Exelixis Inc EXEL.O:EXELIXIS ANNOUNCES PRELIMINARY FISCAL YEAR 2025 FINANCIAL RESULTS, PROVIDES 2026 FINANCIAL GUIDANCE AND OUTLINES KEY PRIORITIES AND MILESTONES FOR 2026EXELIXIS INC: FISCAL YEAR 2026 NET PRODUCT REVENUES GUIDANCE OF $2.325 BILLION - $2.425 BILLIONReuters
Sun, Jan 11
Castle Biosciences 2025 Total Revenue Expected To Exceed $340 Million
Jan 11 (Reuters) - Castle Biosciences Inc CSTL.O:CASTLE BIOSCIENCES ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL–YEAR 2025 RESULTSCASTLE BIOSCIENCES INC - 2025 TOTAL REVENUE EXPECTED TO EXCEED $340 MILLION, ABOVE PREVIOUSLY GUIDED RANGE OF $327-335 MILLIONReuters
Sun, Jan 11
Molecular Partners Says Phase 1/2A Study With Radio-Darpin Mp0712 Initiated
Jan 11 (Reuters) - Molecular Partners AG MOLN.S:MOLECULAR PARTNERS AG - PHASE 1/2A STUDY WITH RADIO-DARPIN MP0712 INITIATEDMOLECULAR PARTNERS AG - PHASE 2 TRIAL OF MP0317 OPEN FOR CHOLANGIOCARCINOMAMOLECULAR PARTNERS AG - PHASE 1/2A TRIAL OF MP0533 ONGOINGReuters
Sun, Jan 11
